RMC-8839, a covalent KRAS G13C inhibitor, induced tumor regressions in selected xenograft models, but one-third of cell lines showed incomplete pathway suppression, revealing that codon 13-mutant RAS differs from other KRAS mutations with decreased stability and increased GTP hydrolysis. (Cancer Discovery)
KRAS G13C Inhibitor Reveals Unique Biology of Codon 13 Mutations
The CRC Digest